Peptide and polypeptide inhibitors of complement C1s

Inactive Publication Date: 2005-12-01
ZYMOGENETICS INC
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010] The present invention provides novel peptides and polypeptides that can inhibit the compleme

Problems solved by technology

Although the complement system plays an important role in providing resistance to infections, an inappropriate activation of compleme

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide and polypeptide inhibitors of complement C1s

Examples

Experimental program
Comparison scheme
Effect test

example 1

C1s Enzyme Assay and Classical Complement Hemolysis Assay

[0159] C1s enzyme assays were performed in 96 well plates preincubated in the assay buffer for 30 minutes at room temperature. Activated human C1s (Calbiochem-Novabiochem Corporation; San Diego, Calif.); final assay concentration: 1.25 μg / ml), was incubated with samples in 50 mM Tris-HCl (pH 8) that contained 116 mM sodium chloride and 0.05% Polysorbate 80. The chromogenic substrate, Pefa-C1E (Centerchem, Inc.; Stamford, Conn.; final assay concentration: 0.4 mM), was added to the assay wells and the plate was read at 405 nm, 37° C., for 30 minutes at 20 second intervals on a SPECTRAmax PLUS plate reader (Molecular Devices Corporation; Sunnyvale, Calif.). Inhibition was determined as a decrease in Vmax, which is calculated as the maximum Δ milli-absorbance units / min over the assay period.

[0160] An assay was performed to determine the effect of BD001 on classical complement hemolysis. A pool of pre-sensitized sheep erythrocyte...

example 2

Effects of Posttranslational Modification on BD001 Activity

[0163] Three types of post-translational modifications have been identified in BD001: (1) glycosylation at Asn23 consisting of a fucosylated complex-type core; (2) sulfation of at least one of Tyr117, Tyr119, and Tyr121; and (3) proteolytic cleavage after Arg65. The first two modifications have been identified in native BD001 as well as recombinant BD001 expressed in Baculovirus. The third modification is seen in a fraction of the recombinant BD001 expressed in Baculovirus. To evaluate the effect of these posttranslational modifications on activity, sulfate groups were removed from recombinant BD001 using aryl sulfatase (Sigma Chemical Co.; St. Louis, Mo.) in 10 mM acetate, 120 mM NaCl (pH 5.5), recombinant BD001 proteins were deglycosylated using PNGase F (CALBIOCHEM-NOVABIOCHEM Corp.; La Jolla, Calif.) in buffer supplied by the manufacturer, and the cleaved recombinant BD001 species was separated from intact BD001 using r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional application No. 60 / 212,998. filed Jun. 21, 2000, and 09 / 883,727, filed Jun. 18, 2001, the contents of which are incorporated by reference.TECHNICAL FIELD [0002] The present invention relates generally to new peptides and polypeptides, which inhibit complement C1s. BACKGROUND OF THE INVENTION [0003] The complement system is considered an ancient part of the immune system, which serves to discriminate self and non-self (see, for example, Rother et al. (Eds.), The Complement System, Second Edition (Springer-Verlag 1998), Morely and Walport, The Complement Factsbook (Academic Press 1999), and Morgan (Ed.), Complement Methods and Protocols (Humana Press, Inc. 2000)). Although the complement system plays an important role in providing resistance to infections, an inappropriate activation of complement can result in a variety of disorders. [0004] There are two main pathways for complement...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/00A61P29/00A61P31/00C07K14/435C07K14/815
CPCA61K38/00C07K14/815C07K14/43536A61P29/00A61P31/00
Inventor WEST, ROBERTSHEPPARD, PAULFOX, BRIAN
Owner ZYMOGENETICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap